Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
Primary Industries
- Drugs
- Biotechnology
- Medical
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3002
License Grant
The Licensor entered into a License Agreement with the Licensee to establish and market its C’elleTM preservation program in mainland China. The Agreement also allows the Licensee to conduct research studies using the Licensor's proprietary C’elle menstrual stem technology to identify future potential therapeutic applications.
License Property
C’elle has the potential to benefit millions of women worldwide, since stem cells found in menstrual blood may potentially be utilized in a broad range of future regenerative therapies to possibly treat a number of debilitating conditions such as heart disease, stroke and diabetes. C’elle stem cells may also have potential to be used in cosmeceutical applications such as anti-aging and wound-healing. The Licensor is one of the world’s largest private cord blood banks and a developer of innovative stem cell solutions.
Field of Use
The rights granted apply to the healthcare industry.
IPSCIO Record ID: 2806
License Grant
The Licensor entered into a definitive License and Royalty Agreement with the India Licensee to establish and market its C’elleSM menstrual stem cell preservation program in India and optionally, into the countries of Bangladesh, Nepal, Pakistan and Sri Lanka. In consideration for the up-front License fee, the Licensor transferred its technology, know-how and quality systems to the Licensee. Once the Licensee has processed 10,000 specimens, the parties have agreed to renegotiate the royalty fee on collection, processing and storage revenues.
License Property
The C'elle(SM) service empowers women to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degree relatives in a manner similar to umbilical cord blood stem cells.
IPSCIO Record ID: 7550
License Grant
The Licensee obtained a non-exclusive License to distribute human embryonic stem cell lines made by the Licensor through stem cell banks.
License Property
The term “stem cells†describe all of the cells that can give rise to the different cells found in tissues. Cells from the same pluripotent stem cells can be used in any patient. This type of cell therapy is referred to as “allogeneicâ€. This permits the use of a single master stem cell bank in the manufacturing of the therapeutic doses to be used such that one uniform source of starting cells can be readily controlled for consistency, lack of infectious agents and cleared by regulatory agencies.
IPSCIO Record ID: 26064
License Grant
Licensor, Chief Scientific Officer of Licensee, hereby grants to Licensee and its Affiliates during the Term an exclusive, worldwide, royalty bearing license, with the right to grant sublicenses through multiple tiers of sublicenses, in and to, the Technology, Licensed Products, Licensed Improvements, and Patents; and to develop, distribute, market, make, have made, use, have used, sell, have sold, offer for sale, and import Licensed Products.
Sublicenses – In the event that Licensee sublicenses any of its rights hereunder to a Sublicense, such sublicense shall include terms and conditions consistent with the terms and conditions of the license granted under this Agreement Sublicenses, if any, granted hereunder, will be to Third Parties in an arm's length transaction under written agreements, copies of which will be provided to Licensor.
License Property
Licensed Technology – Ex Vivo Expansion of Cord Blood Cells Work has demonstrated that cells present in the CB mononuclear (MNC) fraction inhibit ex vivo expansion of the CD34+ cells. This inhibition can be overcome by co-culture on mesenchymal stem cells (MSC) and clinical studies are being undertaken to evaluate the potential of CB MNC cultured on MSC for 2 weeks.
The Company has evaluated the effects of removal of various mature cells by immvno selection and the depleted cells failed to expand. More recently we have evaluated the removal of red blood cells and have positive data for optimal removal of red cells and preliminary evidence that the red cell depleted products may expand up to 500 fold. This approach has a number of advantages including the passive removal of inhibitory cells which has minimal effect on total CD34+ cells. Future studies are required to generate data on the expansion potential of the depleted CB products, and this work will include proof of principle expo performed with frozen CB products to mimic the clinical setting.
The red cell depletion results in recovery of approx. 50 million white cells which would only be a cell dose 0.1 x 107 TNCI & With an expansion of only 100 fold this would result in a cell dose of 10.0 x 10' ThC/kg. Therefore an expansion of 500 fold would be sufficient for all adult patients to achieve a cell dose in the range of 10.0 x 107 TNC/kg, therefore making CB transplantation available to potential patients. In comparison, CD34 selection for expansion results in approx. 5 million cells post selection and would require an expansion of 1,000 fold or more to achieve similar cell doses. No studies have reported these levels of expansion consistently.
Field of Use
Licensee is engaged in research and development of stem cells, cord blood banking and expansion laboratory services and interested in developing and commercializing the Technology.
IPSCIO Record ID: 7221
License Grant
The Licensee entered into a License Agreement with the Licensor to acquire the rights to and to distribute certain intellectual property in China and Brazil.
License Property
The Licensor has developed and markets, a proprietary core processing platform for Adipose (fat) Derived Adult Stem Cells. The Licensor is in the business of collecting, processing, and long term storage of adult stem cells, allowing healthy individuals to privately preserve their stem cells for future use in cell therapy at an affordable price.
Field of Use
The rights granted apply to the medical industry.
The Licensee was not required to pay an upfront fees license fee.
IPSCIO Record ID: 3040
License Grant
The Company entered into a definitive License and royalty Agreement with the Licensor to establish and market its C’elleSM preservation program in India and optionally, into the countries of Bangladesh, Nepal, Pakistan and Sri Lanka.
License Property
In consideration for the up-front License fee, the Company Licensed its technology, know-how and quality systems to the Licensee. Célle's exclusive service provides women with the opportunity to collect and preserve vital stem cells that can be harvested from the body's menstrual fluid during the menstrual cycle.
There are no incremental License fees associated with the expanded Licensed territory.
The Company recognizes revenue from processing fees upon completion of processing and storage fees ratably over the contractual storage period, as well as, other income from royalties paid by licensees related to long term storage contracts which the Company has under license agreements. Contracted storage periods can range from one to twenty-one years. Deferred revenue on the accompanying consolidated balance sheets includes the portion of the annual storage fee and the twenty-one year storage fee that is being recognized over the contractual storage period as well as royalties received from foreign licensees related to long-term storage contracts in which the Company has future obligations under the license agreement.
Field of Use
Célle's exclusive service provides women with the opportunity to collect and preserve vital stem cells that can be harvested from the body's menstrual fluid during the menstrual cycle.
IPSCIO Record ID: 168
License Grant
Licensor hereby grants a royalty-bearing, worldwide, exclusive license, with the right to sublicense, to use the Patent Rights and Know-How to (a) research, develop, make, have made, use, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Products, (b) research, develop, use, practice, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Processes, and (c) develop, use, perform, sell, have sold, offer for sale, have offered for sale, import, have imported, export and have exported Licensed Services.
Company granted an exclusive license to use its “ACTCellerate†embryonic stem cell technology and a bank of over 140 diverse progenitor cell lines derived using that technology.
License Property
ACTCellerateâ„¢ is a recently discovered technology that allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate between embryonic stem cells and fully differentiated cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of embryonic stem cells. Using the ACTCellerate platform technology over 140 distinguishable novel progenitor cell lines have already been created, scaled-up, and banked. These unique cell lines may possess the ability to become a wide array of products never before available to the medical community, with potential applications in research, drug discovery, and human regenerative stem cell therapy.
The licensed rights include pending patent applications, knowledge and the existing bank of cell lines. The licence is exclusive and worldwide for all commercial purposes, including the development of research products, and therapeutic and diagnostic products for human and veterinary use. Licensor has an option to reacquire rights to use the technology for the development of certain types of SCs for human therapeutic use in fields re-lated to its core business.
The technology allows the rapid isolation of novel, highly-purified embryonic progenitor cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of ESCs. These unique cell lines may have potential applications in research, drug discovery and human regenerative SC therapy.
Patent Rights
103080-069-WO1 (PCT/US06/13519, filed on 4-11-06) Novel uses of cells with Prenatal Patterns of prenatal gene expression, published as WO2007/058671
103080-071-P61 (USSN 60/791,400, filed on Apr. 11, 2006) Methods to accelerate the isolation of novel cell strains from pluripotent ST
103080-071-P66 (USSN 60/850,294, filed on Oct. 6, 2006), Methods to accelerate the isolation ov novel cell strains from pluripotent stem cells
103080-071-P01 (USSN 11/604,047, filed on Nov. 21, 2006), Methods to accelerate the isolation of novel cell strains from pluripotent STE…
PCT is 103080-071-WO2 (PCT/US2006/45352, filed on Nov. 21, 2006), published as WO 2007/062198.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
